NAD+ is currently offered in two very different application models: at-home and in clinical settings. At-home options may include oral capsules, sublingual products, or self-injection kits shipped directly to the user. Clinic-based treatment typically involves intravenous infusions administered by trained staff in a wellness clinic, IV therapy center, or medical office. In this guide, we directly compare both approaches, considering what each involves, their practical advantages, and limitations.
What does home use of NAD+ actually involve?
At-home NAD+ products can generally be divided into two main categories. The first includes oral products, such as capsules, tablets, powders, and sublingual forms. These typically contain NAD+ precursors, such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), rather than NAD+ itself, due to the absorption issues discussed elsewhere in our NAD+ guides. The second category includes self-administered injectable products, which may require reconstitution of lyophilized powder or the use of a pre-filled pen, typically for subcutaneous administration.
Oral products used at home have been studied much more thoroughly than NAD+ preparations intended for self-injection. Many randomized, placebo-controlled human studies have used daily oral NR or NMN capsules, which participants took on their own at home without clinical supervision for each dose. These studies make up a significant portion of the evidence base discussed in our other guides [1,2]. DIY NAD+ injection kits are different because they may require the user to reconstitute the product, measure the intended amount, and perform the injection themselves. We discuss these practical steps in more detail in our separate injection guide. In many cases, a doctor or other specialist is not physically present during each administration, although some services may provide initial in-person training or telehealth instruction before independent use begins.
Intravenous therapy in a clinic: what does home use not offer?
IV therapy at the clinic provides several practical elements that home-use products cannot provide in the same way. These include direct supervision during the session, professional insertion and monitoring of the intravenous access, immediate access to trained personnel in the event of a reaction, and eliminating the need for self-injection for individuals who feel uncomfortable with it or do not wish to manage the procedure themselves.
However, it is important to separate the practical value of supervision from the strength of clinical evidence supporting the effects frequently attributed to commercial NAD+ infusions. Clinical trials involving intravenous NAD+ have been conducted under supervised medical conditions. This includes a randomized, placebo-controlled trial in individuals with heart failure that used a low, controlled daily dose for a short and clearly defined treatment period [3]. However, a 2026 systematic review found no eligible controlled outcome studies evaluating intravenous or intramuscular NAD+ for general anti-aging or wellness purposes, which are frequently promoted by commercial IV clinics [4]. This means that clinical supervision itself is a real and significant feature of treatment in a clinic, particularly since a retrospective review of real-world use of commercial IV NAD+ showed more gastrointestinal and cardiac symptoms compared to intravenous nicotinamide riboside used in the same settings [5]. These are reactions where the presence of trained personnel can be useful for observation and appropriate response. At the same time, the broader wellness claims associated with many commercial IV infusions are not supported by the same level of controlled research as some of the data regarding oral NR or NMN.
Cost comparison: at-home kits versus in-clinic sessions
The cost structure of home and clinical use of NAD+ differs significantly. Much of this difference stems from what, aside from the compound itself, is included in the service.
At-home oral supplements, such as NR or NMN capsules, are typically less expensive with regular use because the cost primarily covers the manufactured product. Facility costs, clinical staff time, and direct supervision are not factored into each dose. Monthly costs vary depending on the brand, dosage, formulation, and specific compound, but oral products generally involve lower ongoing costs than in-clinic IV sessions.
At-home injection kits usually cost more per dose than oral supplements because injectable products may require more demanding manufacturing, sterility, packaging, and shipping conditions. Even so, they can cost less than in-clinic intravenous therapy because they do not involve ongoing staff time or facility visits.
Intravenous sessions at a clinic are typically the most expensive option per session, because their price includes infusion equipment, clinical staff time, catheter insertion and monitoring, supervision during the infusion, and general facility overhead. Sessions can last from about 45 minutes to several hours, depending on the protocol and service provider. Some clinics also recommend repeating sessions weekly, bi-weekly, or monthly instead of a single visit, so the total cost of long-term clinical treatment can become significantly higher than the cost of an oral regimen used for a similar period.
Because controlled clinical evidence regarding intravenous NAD+ for general wellness use remains more limited than the data available for oral NAD+ precursors, the higher regular cost of in-clinic IV therapy should also be considered in the context that this route of administration currently has less support from controlled human outcome studies for general wellness claims than cheaper oral alternatives [4].
Security and supervision issues
Home and clinical models involve different kinds of safety issues. It is more precise to state that they have different risk profiles than to assume that one option is always safer than the other.
Oral supplements used at home have been utilized in a larger number of controlled human studies and, at the doses studied, generally showed good tolerability. Some studies reported mild and self-limiting effects, such as headache, gastrointestinal discomfort, and fatigue [1,2]. Because these products are typically taken without direct clinical supervision, the primary practical safety issue is observing the body's response and recognizing when a symptom may require discontinuation of use or medical consultation.
Home injection kits come with additional risks that go beyond the compound itself. These may include proper preparation or reconstitution, maintaining sterility, proper sharps disposal, and recognizing when a local or systemic reaction requires professional medical attention. We discuss these issues in more detail in our injection guide. In a home setting, these tasks are performed without the physical presence of a specialist during each administration.
Intravenous therapy in the clinic provides immediate supervision during administration. This may be significant because in real-world observational data, intravenous NAD+ was associated with a greater number of gastrointestinal and cardiac symptoms than intravenous nicotinamide riboside under the same conditions [5]. In a supervised clinic, trained personnel can monitor vital signs, respond to symptoms, or modify the infusion as needed.
Generally, oral supplementation at home currently has the largest base of controlled safety data among the options discussed here. Home injections introduce additional issues related to self-administration and sterility. In-clinic intravenous therapy provides direct supervision, which may be relevant in light of systemic reactions described during IV use, even if the broader wellness effects often attributed to these services do not yet have the same level of support from controlled studies as oral precursors.
Which option better suits different purposes: convenience or medical supervision?
Instead of treating this issue as a simple question of which option is „better,” it is more useful to consider what a person's priorities are and what the available evidence actually supports.
If the primary priority is choosing the pathway with the strongest available base of controlled human trials while simultaneously limiting costs and logistical burdens, oral NR or NMN has a larger published clinical trial base than the other options discussed here [1,2]. These products can typically be taken at home without a clinic visit or direct supervision with each dose. This does not mean their efficacy has been proven for every effect commonly attributed to NAD+, but they are significantly better studied than self-administered injections or commercial wellness IV protocols.
If the priority is specifically to bypass gastrointestinal absorption while maintaining medical supervision, intravenous administration in a clinic ensures direct observation during therapy. This may be significant in light of the tolerance data described above. However, the broader health and wellness effects often attributed to intravenous NAD+ remain less supported by controlled human trials than the biomarker and safety data available for oral precursors [4,5].
If a non-oral route is a priority without the need for regular clinic visits, home injection kits offer a different model. They reduce the time and costs associated with facility visits, but at the same time shift the responsibilities regarding preparation, maintaining sterility, disposal, and recognizing reactions requiring assistance to the user. Controlled studies directly evaluating this model remain limited.
Claims that specific at-home products or NAD+ kits are unambiguously the „best” choice for effects such as sleep, immune system function, cell repair, or mood should be treated with caution. No controlled clinical trials have been identified that directly compare various at-home NAD+ products against one another regarding these specific effects. Therefore, terms such as „top-rated,” „best,” or exceptionally effective for a specific purpose are not supported by direct comparative clinical evidence.
When comparing options, it is more scientific to consider the specific compound, formulation, route of administration, evidence supporting that route, known safety information, costs, and the degree of clinical supervision than to rely on marketing categories or promises regarding effects.
Regardless of the approach being considered, consultation with a qualified healthcare professional may be appropriate, especially for individuals with medical conditions, those taking prescription medications, or those considering injection or intravenous administration. None of the options discussed here should be considered completely risk-free or suitable for everyone.
Limitations of current evidence
- Controlled clinical trial data on intravenous NAD+ are much more limited than data on oral precursors NR and NMN. A 2026 systematic review found no eligible controlled outcome trials supporting the general wellness or anti-aging claims commonly associated with commercial IV NAD+ services [4].
- Data comparing the tolerability of intravenous NAD+ and intravenous nicotinamide riboside come from a single retrospective, real-world study rather than a randomized controlled trial [5].
- No published studies have been identified that directly compare home NAD+ injection kits with intravenous NAD+ administration in a clinic in terms of safety, efficacy, or clinical outcomes.
- No controlled clinical trials directly comparing different home NAD+ products for specific effect categories, such as sleep, immune function, mood, or cellular repair, have been identified. Therefore, marketing claims such as „best for X” are not supported by direct comparative clinical data.
- Clinical trial evidence for oral NR or NMN cannot be automatically applied to injectable or intravenous NAD+, as the route of administration, formulation, pharmacokinetics, level of oversight, and product quality may differ.
- The mere fact that medical supervision is present during an intravenous session does not prove that the therapy provides a clinical benefit for a specific disease or wellness goal.
- Lower cost, greater convenience, or a more intensive route of administration should not be interpreted as evidence of greater efficacy.
Disclaimer
The article is for educational and scientific-informational purposes only. It does not constitute medical advice, a diagnosis, therapeutic recommendations, or a recommendation to use any NAD+ product or specific route of administration.
NAD+ and its precursors, in the forms and routes of administration discussed here, should not be presented as FDA- or EMA-approved methods for preventing, treating, or curing diseases, unless referring to a specific approved medicinal product and indication. Simply demonstrating changes in NAD+-related biomarkers does not constitute proof of clinical benefit.
Before starting the use of a supplement, an injectable product intended for self-administration, or intravenous therapy in a clinic, you should consult a qualified healthcare professional, especially during pregnancy or breastfeeding, when treating a chronic illness, including cardiovascular disease, or while concurrently using prescription medications.
References
[1] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[2] Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://doi.org/10.1038/s41598-019-46120-z
[3] American Journal of Cardiovascular Drugs. (2026). Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: A randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12779688/
[4] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057
[5] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582